inclusion criteria: 1. provides proven legal identity. 2. provides written informed consent prior to initiation of any study procedures. 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. 4. agrees to the collection of venous blood per protocol. 5. male or non-pregnant female subjects, 18-55 years of age at the time of enrollment. 6. male or female of childbearing potential must agree to use or have practiced true abstinence or use at least two acceptable primary form of contraception from first vaccination until 60 days after the last vaccination. 7. women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination. 8. healthy subjects who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. 9. oral temperature is less than 37.5 °c. 10. pulse less than 100 beats per minute. 11. blood pressure (bp) less than 140/90 mm hg, inclusive. (appendix i) 12. clinical screening laboratory evaluations (white blood cell (wbc), hemoglobin (hgb), platelets (plts), alanine transaminase (alt), aspartate transaminase (ast), creatinine (cr), alkaline phosphatase (alp), total bilirubin (t. bili), prothrombin time (pt), partial thromboplastin time (ptt) and hba1c) are within acceptable normal reference ranges at the clinical laboratory being used. 13. must agree to refrain from donating blood or plasma during the study (outside of this study).

inclusion criteria: 1. provides proven legal identity. 2. provides written informed consent prior to initiation of any study procedures. 3. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. 4. agrees to the collection of venous blood per protocol. 5. male or non-pregnant female subjects, 18-55 years of age at the time of enrollment. 6. male or female of childbearing potential must agree to use or have practiced true abstinence or use at least two acceptable primary form of contraception from first vaccination until 60 days after the last vaccination. 7. women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination. 8. healthy subjects who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. 9. oral temperature is less than 37.5 °c. 10. pulse less than 100 beats per minute. 11. blood pressure (bp) less than 140/90 mm hg, inclusive. (appendix i) 12. clinical screening laboratory evaluations (white blood cell (wbc), hemoglobin (hgb), platelets (plts), alanine transaminase (alt), aspartate transaminase (ast), creatinine (cr), alkaline phosphatase (alp), total bilirubin (t. bili), prothrombin time (pt), partial thromboplastin time (ptt) and hba1c) are within acceptable normal reference ranges at the clinical laboratory being used. 13. must agree to refrain from donating blood or plasma during the study (outside of this study).

inclusion criteria: provides proven legal identity. provides written informed consent prior to initiation of any study procedures. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. agrees to the collection of venous blood per protocol. male or non-pregnant female subjects, 18-55 years of age at the time of enrollment. male or female of childbearing potential must agree to use or have practiced true abstinence or use at least two acceptable primary form of contraception from first vaccination until 60 days after the last vaccination. women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination. healthy subjects who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. oral temperature is less than 37.5 °c. pulse less than 100 beats per minute. blood pressure (bp) less than 140/90 mm hg, inclusive. (appendix i) clinical screening laboratory evaluations (white blood cell (wbc), hemoglobin (hgb), platelets (plts), alanine transaminase (alt), aspartate transaminase (ast), creatinine (cr), alkaline phosphatase (alp), total bilirubin (t. bili), prothrombin time (pt), partial thromboplastin time (ptt) and hba1c) are within acceptable normal reference ranges at the clinical laboratory being used. must agree to refrain from donating blood or plasma during the study (outside of this study).

inclusion criteria: provides proven legal identity. provides written informed consent prior to initiation of any study procedures. willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures. agrees to the collection of venous blood per protocol. male or non-pregnant female subjects, 18-55 years of age at the time of enrollment. male or female of childbearing potential must agree to use or have practiced true abstinence or use at least two acceptable primary form of contraception from first vaccination until 60 days after the last vaccination. women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination. healthy subjects who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study. oral temperature is less than 37.5 °c. pulse less than 100 beats per minute. blood pressure (bp) less than 140/90 mm hg, inclusive. (appendix i) clinical screening laboratory evaluations (white blood cell (wbc), hemoglobin (hgb), platelets (plts), alanine transaminase (alt), aspartate transaminase (ast), creatinine (cr), alkaline phosphatase (alp), total bilirubin (t. bili), prothrombin time (pt), partial thromboplastin time (ptt) and hba1c) are within acceptable normal reference ranges at the clinical laboratory being used. must agree to refrain from donating blood or plasma during the study (outside of this study).